Literature DB >> 3135497

Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

E Girardin1, G E Grau, J M Dayer, P Roux-Lombard, P H Lambert.   

Abstract

Because of the possible involvement of cytokines in gram-negative septicemia, we investigated serum levels of tumor necrosis factor alpha, interleukin-1 beta, alpha interferon, and gamma interferon in children with gram-negative sepsis and purpura fulminans. We studied 55 patients (ages, 1 month to 19 years) with a clinical diagnosis of sepsis and purpuric lesions who were in shock or had three or more other biologic risk factors. The mortality rate was correlated with the number of risk factors present on admission to the hospital (P = 0.03). Tumor necrosis factor alpha was elevated in 91 percent of the 35 patients tested, interleukin-1 in 21 percent of the 33 patients tested, and gamma interferon in 19 percent of the 32 tested. Alpha interferon levels were within normal limits in the 32 patients tested. Serum levels of tumor necrosis factor alpha were positively correlated with the number of risk factors (P less than 0.05) and negatively correlated with blood fibrinogen levels (P = 0.01). Tumor necrosis factor alpha, interleukin-1, and gamma interferon were significantly higher in patients who died than in the survivors. Alpha interferon levels were similar in the two groups. Serum concentrations of both interleukin-1 and gamma interferon were correlated with concentrations of tumor necrosis factor alpha. These data provide evidence that serum levels of tumor necrosis factor alpha, interleukin-1, and gamma interferon correlate with the severity of meningococcemia in children. The findings may have implications for new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135497     DOI: 10.1056/NEJM198808183190703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  153 in total

1.  Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS).

Authors:  S S Qureshi; S M Lewis; V A Gant; D Treacher; B H Davis; K A Brown
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 2.  Pathophysiology of meningococcal meningitis and septicaemia.

Authors:  N Pathan; S N Faust; M Levin
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

Review 3.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 4.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

5.  Sepsis and tumor necrosis factor--bedfellows that cannot be ignored.

Authors:  H R Michie; D W Wilmore
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

6.  Tumor necrosis factor in human disease.

Authors:  L F Fajardo; G E Grau
Journal:  West J Med       Date:  1991-01

7.  Tumour necrosis factor-alpha in infectious meningitis.

Authors:  D Nadal; D Leppert; K Frei; P Gallo; H Lamche; A Fontana
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

8.  Diminished cord blood lymphocyte L-selectin expression in neonatal bacterial infection.

Authors:  C Bührer; U Luxenburger; B Metze; E Kattner; G Henze; J W Dudenhausen; M Obladen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

9.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

Authors:  A Seekamp; J S Warren; D G Remick; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

10.  Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Authors:  H Jin; R Yang; S Marsters; A Ashkenazi; S Bunting; M N Marra; R W Scott; J B Baker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.